Evidence map›Paper›PMID 39702937›Full record

ArticleThe Prostate2025

The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or TNM Staging.

Sajeev Sridhar, Zeyad Abouelfetouh, Ion Codreanu, Nakul Gupta, Shu Zhang, Eleni Efstathiou, Daniel K Karolyi, Steven S Shen, Peter S LaViolette, Brian Miles and 1 more

Abstract read
In one paragraph

Article in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. An Innovative Approach with [Diagnostics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sajeev SridharDepartment of Radiology, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0001-5320-2958
Zeyad AbouelfetouhDepartment of Radiology, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0002-0563-2061
Ion CodreanuDepartment of Radiology, Houston Methodist Research Institute, Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Moldova.ORCID 0000-0002-2644-5572
Nakul GuptaDepartment of Radiology, Houston Methodist Hospital, Houston Methodist Research Institute, Houston Radiology Associated, Houston, Texas, USA.ORCID 0000-0002-2413-2193
Shu ZhangDepartment of Radiology, Houston Methodist Research Institute, Houston, Texas, USA.
Eleni EfstathiouDepartment of Medicine, Houston Methodist Hospital, Houston Methodist Oncology Partners, Houston, Texas, USA.
Daniel K KarolyiDepartment of Radiology, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
Steven S ShenDepartment of Pathology, Houston Methodist Hospital, Houston Methodist Research Institute, Houston, Texas, USA.
Peter S LaVioletteDepartment of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0002-9602-6891
Brian MilesDepartment of Urology, Houston Methodist Hospital, Houston Methodist Urology Associates, Houston, Texas, USA.
Diego R MartinDepartment of Pathology, Houston Methodist Hospital, Houston Methodist Research Institute, Houston, Texas, USA.

Funding

Advancing MRI technology for early diagnosis of liver metastasesR01CA245920 · NCI · UNIVERSITY OF ARIZONA · PI ALTBACH, MARIA I., MARTIN, DIEGO R · 2020 to 2024
$2.4M
NCI NIH HHS R01 CA245920This research was supported by the NIH 1R01CA245920-02. MD Anderson Foundation. Houston Methodist Neal Cancer Center.
6 · The paper itself

Abstract

backgroundDynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) in the current Prostate Imaging-Reporting and Data System version 2.1 (PI-RADS v2.1) is considered optional, with primary scoring based on T2-weighted imaging (T2WI) and diffusion weighted imaging (DWI). Our study is designed to assess the relative contribution of DCE MRI in a patient-cohort with whole mount prostate histopathology and spatially-mapped prostate adenocarcinoma (PCa) for reference.

methodsWe performed a partially-blinded retrospective review of 47 prostatectomy patients with recent multi-parametric MRI (mpMRI). Scans included T2WI, DWI with apparent diffusion coefficient (ADC) mapping, and DCE imaging. Lesion conspicuity was scored on a 10-point scale with ≥ 6 considered "positive," and image quality was assessed on a 4-point scale for each sequence. The diagnostic contribution of DCE images was evaluated on a 4-point scale. The mpMRI studies were assigned PI-RADS scores and tumor, node, metastasis (TNM) T-stage with blinded comparison to spatially-mapped whole-mount pathology. Results were compared to the prospective clinical reports, which used standardized PI-RADS templates that emphasize T2WI, DWI and ADC.

resultsPer lesion sensitivity for PCa was 93.5%, 82.6%, 63.0%, and 58.7% on T2WI, DCE, ADC and DWI, respectively. Mean lesion conspicuity was 8.5, 7.9, 6.2, and 6.1, on T2W, DCE, ADC and DWI, respectively. The higher values on T2WI and DCE imaging were not significantly different from each other but were both significantly different from DWI and ADC (p < 0.001). DCE scans were determined to have a marked diagnostic contribution in 83% of patients, with the most common diagnostic yield being detection of contralateral peripheral zone tumor or delineating presence/absence of extra-prostatic extension (EPE), contributing to more accurate PCa staging by PI-RADS or TNM, as compared to histopathology.

conclusionWe demonstrate that DCE may contribute to lesion detection and local staging as compared to T2WI plus DWI-ADC alone and that lesion conspicuity using DCE is markedly improved as compared to DWI-ADC. These findings support modification of PI-RADS v2.1 to include use of DCE acquisitions and that a TNM staging is feasible on mpMRI as compared to surgical pathology.

Indexed as

AdenocarcinomaMagnetic Resonance ImagingProstateProstatic NeoplasmsAgedCohort StudiesContrast MediaDiffusion Magnetic Resonance ImagingDynamic Contrast Enhanced Magnetic Resonance ImagingHumansMaleMiddle AgedNeoplasm StagingProstatectomyRetrospective StudiesContrast MediaADCconspicuityDCEDWIMRIPI‐RADSprostate cancerT2W

Identifiers

PMID39702937
PMCPMC11848987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.